Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
J Crit Care ; 53: 69-74, 2019 10.
Artículo en Inglés | MEDLINE | ID: mdl-31202160

RESUMEN

PURPOSE: The specific norepinephrine dose at which epinephrine should be added in septic shock is unclear. This study sought to determine the norepinephrine-equivalent dose at epinephrine initiation that correlated with hemodynamic stability. METHODS: Septic shock patients receiving both norepinephrine and epinephrine were included in this study. Classification and regression tree analysis was conducted to determine breakpoints in norepinephrine-equivalent dose predicting hemodynamic stability, with two cohorts identified. The primary outcome was hemodynamic stability, and secondary outcomes were shock-free survival, time to achieve hemodynamic stability, and change in SOFA score. RESULTS: Optimal dose group was identified as initiating epinephrine when norepinephrine-equivalent dose was between 37 and 133 µg/min. A total of 138 and 61 patients were classified in optimal and non-optimal dose groups, respectively. Baseline characteristics were similar between groups except vasopressin use was more frequent in the optimal dose group. More patients in optimal dose group versus non-optimal dose group achieved hemodynamic stability (40 [29%] vs. 9 [14.8%]), absolute risk difference 14.2% [95% CI 2.5-25.9%]; p = .03). On multivariable analysis, initiating epinephrine within the optimal norepinephrine-equivalent dose range was independently associated with higher odds of hemodynamic response (OR 3.06 [95% CI 1.2-7.6]; p = .02). No differences were observed in other secondary outcomes. CONCLUSIONS: Initiation of epinephrine when patients were receiving norepinephrine-equivalent doses of 37-133 µg/min was associated with a higher rate of hemodynamic stability.


Asunto(s)
Epinefrina/administración & dosificación , Hemodinámica/efectos de los fármacos , Norepinefrina/administración & dosificación , Choque Séptico/tratamiento farmacológico , Vasoconstrictores/administración & dosificación , Anciano , Quimioterapia Combinada , Femenino , Humanos , Masculino , Persona de Mediana Edad , Neurofisinas/metabolismo , Precursores de Proteínas/metabolismo , Estudios Retrospectivos , Choque Séptico/fisiopatología , Vasopresinas/administración & dosificación , Vasopresinas/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA